{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hitchon CA"],"funding":["Public Health Agency of Canada- COVID-19 Immunity Task Force."],"pagination":["1130"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12656540"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(11)"],"pubmed_abstract":["<h4>Background</h4>Vaccination reduces Coronavirus disease-19 (COVID-19) infection severity. We evaluated COVID-19 vaccine uptake and effectiveness in people with immune mediated inflammatory diseases (pIMIDs) versus the general population.<h4>Methods</h4>Using population-based administrative health records, we identified cohorts between 2004 and 2022 with an IMID (rheumatoid arthritis <i>n</i> = 10,405, systemic autoimmune rheumatic disease <i>n</i> = 5888, inflammatory bowel disease <i>n</i> = 7911, multiple sclerosis <i>n</i> = 3665, psoriasis <i>n</i> = 23,948) who were matched (1:5) by age, sex, and region to general population comparators (<i>n</i> = 243,490) without these IMIDs. Between 1 January 2021 and 31 March 2022, rates of COVID-19 vaccine administration, hospitalizations with"],"journal":["Vaccines"],"pubmed_title":["COVID-19 Vaccination, Hospitalization Rates, and Mortality Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-Based Study."],"pmcid":["PMC12656540"],"funding_grant_id":["2122-HQ-000070"],"pubmed_authors":["Widdifield J","Bernstein CN","Marrie RA","Hitchon CA","Taylor C","Peschken CA","Kaplan GG","Lacaille D"],"additional_accession":[]},"is_claimable":false,"name":"COVID-19 Vaccination, Hospitalization Rates, and Mortality Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-Based Study.","description":"<h4>Background</h4>Vaccination reduces Coronavirus disease-19 (COVID-19) infection severity. We evaluated COVID-19 vaccine uptake and effectiveness in people with immune mediated inflammatory diseases (pIMIDs) versus the general population.<h4>Methods</h4>Using population-based administrative health records, we identified cohorts between 2004 and 2022 with an IMID (rheumatoid arthritis <i>n</i> = 10,405, systemic autoimmune rheumatic disease <i>n</i> = 5888, inflammatory bowel disease <i>n</i> = 7911, multiple sclerosis <i>n</i> = 3665, psoriasis <i>n</i> = 23,948) who were matched (1:5) by age, sex, and region to general population comparators (<i>n</i> = 243,490) without these IMIDs. Between 1 January 2021 and 31 March 2022, rates of COVID-19 vaccine administration, hospitalizations with","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-05-19T03:21:50.687Z","creation":"2026-05-19T03:11:55.606Z"},"accession":"S-EPMC12656540","cross_references":{"pubmed":["41295504"],"doi":["10.3390/vaccines13111130"]}}